Login
$EDSA
$1.89 -$0.05 (2.84%) Live

$EDSA 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more

TORONTO and TOKYO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, and KYORIN Pharmaceuti...

23 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

15 Oct 2026 8-K: Other Events

On October 15, 2026, Edesa Biotech, Inc. (the “Company”) reported that the U.S. Food and Drug Administration (“FDA”) has cleared the Company's Investigational New Drug (“IND”) application for its Phase 2 clinical study of EB06 in vitilig...

20 Aug 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Pre-Funded Warrants to Purchase up to 675,000 Common Shares,

13 Aug 2026 8-K: Results of Operations and Financial Condition

TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results ...

11 Jun 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 10, 2026, by and among Edesa Biotech, Inc., a British Columbia corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement...

05 Jun 2026 8-K: Other Events

On June 5, 2026, Edesa Biotech, Inc. (the “Company”) reported favorable exploratory data for paridiprubart, its first-in-class anti-TLR4 monoclonal antibody, in patients with acute kidney injury (“AKI”) and respiratory distress.

29 May 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

This Amendment No. 5 to the Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan (this “Amendment”) is made and entered into effective as of March 18, 2026 (the “Effective Date”), by Edesa Biotech, Inc., a British Columbia corpora...

15 May 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

14 May 2026 8-K: Results of Operations and Financial Condition

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results f...

24 Feb 2026 8-K: Other Events

On February 24, 2026, Edesa Biotech, Inc. (the “Company”) announced positive additional data from a Phase 3 study of paridiprubart.

13 Feb 2026 8-K: Results of Operations and Financial Condition

TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results ...

12 Dec 2025 8-K: Other Events

We have acted as Canadian legal counsel to Edesa Biotech, Inc., a British Columbia corporation (the “Company”), in connection with a continuous “at-the-market” offering (the “Offering”) of up to 1,292,861 common shares of the Company, no...

12 Dec 2025 8-K: Results of Operations and Financial Condition

TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results ...

28 Oct 2025 8-K: Other Events

On October 8, 2025, Edesa Biotech, Inc. (the “Company”) announced positive results from a Phase 3 study evaluating the Company’s drug candidate paridiprubart (EB05) as a treatment for Acute Respiratory Distress Syndrome (“ARDS”), a life-...

30 Sep 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

As previously disclosed, on October 12, 2023, Edesa Biotech Research, Inc. (“Edesa Biotech Research”), a wholly owned subsidiary of Edesa Biotech, Inc. (the “Company”), and the Company, as guarantor, entered into a multi-year contributio...

09 Sep 2025 8-K: Other Events

We have acted as Canadian legal counsel to Edesa Biotech, Inc., a British Columbia corporation (the “Company”), in connection with a continuous “at-the-market” offering (the “Offering”) of up to 2,289,453 common shares of the Company, no...

08 Aug 2025 8-K: Results of Operations and Financial Condition

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results ...

28 May 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

This Amendment No. 4 to the Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan (this “Amendment”) is made and entered into effective as of March 18, 2025 (the “Effective Date”), by Edesa Biotech, Inc., a British Columbia corpora...

14 May 2025 8-K: Results of Operations and Financial Condition

TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results f...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support